“…Nevertheless, Korea has a rather high incidence of advanced lung cancer. 39,40 As four fifths of the clinical stage of NSCLC at diagnosis were stage III or IV, its limitation and influence would be lessened. Furthermore, polymorphisms as either prognostic or predictive biomarkers have many advantages, especially in advanced cancer settings.…”